They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...

MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, sequenced with Regeneron’s (REGN) immune ...

IO Biotech (IOBT) announced the publication of results from a preclinical study of its second immune-modulatory therapeutic cancer vaccine candidate, IO112, targeting arginase 1, in the Journal ...

So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

The BioXplorer 100 from H.E.L is a multi-bioreactor system that has been specifically developed for the optimization of aerobic fermentations. Having a working volume as low as 50 mL, the ...

Plastic is the most prevalent marine pollutant, and plastic surfaces are the fastest growing habitat in the ocean. Researchers at the University of Hawai'i (UH) at Mānoa have recently discovered ...

Merck's (NYSE:MRK) recent acquisition of rights to Chinese biotech LaNova Medicines' cancer candidate LM-299 in a deal worth up to $3.3B underscores Big Pharma's appetite for best-in-class assets ...

While 2024 was a “challenging” year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months. On November 28 ...

A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...

Prolium was set up by RTW in 2024. Last year also saw the New York-based investment fund involved in the launch of obesity biotech Kailera Therapeutics, which RTW said at the time was the fourth ...